Go to Health Care Provider version
| Diagnosis | Acute Lymphoblastic Leukemia | Study Status | Open |
| Phase | I |
| Age | Child, Adult - (1 Year to 21 Years) | Randomisation | NO |
| Line of treatment | Disease relapse or progression |
| Routes of Treatment Administration | intravenous (carfilzomib); Other drugs as usually administered for leukemia therapy
|
| Last Posted Update | 2021-09-03 |
| ClinicalTrials.gov # | NCT02303821 |
International Sponsor
AmgenPrincipal Investigators for Canadian Sites
CHU Ste-Justine - Dr. Henrique Bittencourt
Centres
Medical contact
Dr. Henrique Bittencourt
Dr. Monia Marzouki
Dr. Sebastien Perreault (neuro-onc)
Social worker/patient navigator contact
Marie-Claude Charrette
Clinical research contact
Marie Saint-Jacques
Study Description
This phase I/II trial is trying to determine how much carfilzomib (an anti-cancer drug) should be used, alone and in combination with induction chemotherapy, to treat children with acute lymphoblastic leukemia that has come back (relapsed) or is refractory to treatment. Carfilzomib is an anti-cancer medication called proteasome inhibitor and is given intravenously.
Inclusion Criteria
- Age 1 year to 21 years
- Acute lymphoblastic leukaemia that has come back (relapsed) or is refractory to treatment
- Multiple other inclusion and exclusion criteria could apply and will be reviewed by your treating team
